MedTrace Logo

Study Evaluating Safety And Tolerability, Solid Tumor

NCT00768469 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-11-19

Study results available
· View outcomes & findings →

Summary

This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

Neratinib

Administered orally, continuous, once daily.

DRUG

Paclitaxel

Administered IV, on days 1, 8, 15 of 28 day cycle.

Sponsors & Collaborators

  • Puma Biotechnology, Inc.

    lead INDUSTRY

Principal Investigators

  • Puma · Biotechnology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768469 on ClinicalTrials.gov